Business Context and Reporting Period
Disc Medicine, Inc. (Nasdaq: IRON), a biopharmaceutical company, filed a Current Report on Form 8-K dated February 13, 2023. The filing announces the entry into a Material Definitive Agreement for a registered direct offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered Direct Offering.
- Securities Issued: 1,488,166 shares of Common Stock and 1,229,224 Pre-Funded Warrants.
- Purchase Price: $23.00 per share of Common Stock; $22.9999 per Pre-Funded Warrant.
- Gross Proceeds: Approximately $62.5 million (before offering expenses).
- Use of Proceeds: Funding research and clinical development of product candidates, working capital, and potential in-licenses, acquisitions, or investments.
- Expected Closing: On or about February 15, 2023.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Terms
The primary material change is the capital raise via the Offering. Key terms include:
- Pre-Funded Warrants: Exercisable at any time after issuance with an exercise price of $0.0001 per share.
- Beneficial Ownership Limitation: Holders cannot exercise warrants if it would result in beneficial ownership exceeding 9.99% of outstanding shares immediately after exercise. This limit can be adjusted by the holder with 61 days' notice, up to a maximum of 19.99%.
- Registration: Securities were offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-269272).
Outlook, Risks, and Management Commentary
Management intends to use the net proceeds to advance the company's clinical pipeline and general corporate purposes, including potential strategic transactions. The filing contains forward-looking statements regarding the completion of the offering, the timing of development, and regulatory status. These statements are subject to risks and uncertainties, including those related to financial results and the successful completion of the offering, as detailed in the company's previous SEC filings (e.g., Form 8-K filed December 29, 2022).
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting offering expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Confirm the impact of the new share issuance on existing shareholder dilution.
- Monitor subsequent filings for updates on the specific allocation of funds to clinical trials or acquisitions.